Showing 1021-1030 of 8728 results for "".
The State of Academic Dermatology
https://practicaldermatology.com/topics/practice-management/the-state-of-academic-dermatology/18843/In this edition of Derm Insider, host Neal Bhatia, MD sits down with Jane Grant-Kels, MD, Sheila Fallon Friedlander, MD, and Kevin Cooper, MD to discuss the challenges and rewards of academic dermatology. From meeting aggressive budgets to dealing with EMRs, academicians face many of the same demandAssessing the Aging Face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/assessing-the-aging-face/18849/Jason Emer, MD discusses the evolving filler market and new trends in facial rejuvenation treatments. He offers tips for assessing patients globally—in three and four dimensions—in order to choose the right options for contouring the face with fillers and fat in order to give patients the most naturDermWireTV Update
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-update/19125/Allergan is business as usual following a revised merger offer from Valeant. Get an update on the offer and Allergan's recent nominationfor the Prixe Galien USA.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Journal Club: Treating Itch and Lessons from the IL-4 and IL-13 Blockade
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-treating-itch-and-lessons-from-the-il-4-and-il-13-blockade/27025/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Matthew Zirwas, MD, about how evaluations of itch can lead to treatment for atopic dermatitis, and his Journal of Drugs in Dermatology article "Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade."Hilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inDermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent e